vs
Cardio Diagnostics Holdings, Inc.（CDIO）与QuidelOrtho Corp（QDEL）财务数据对比。点击上方公司名可切换其他公司
QuidelOrtho Corp的季度营收约是Cardio Diagnostics Holdings, Inc.的196877.6倍（$699.9M vs $3.6K）。QuidelOrtho Corp同比增速更快（-3.7% vs -21.2%）。Cardio Diagnostics Holdings, Inc.自由现金流更多（$-5.9M vs $-94.7M）。过去两年QuidelOrtho Corp的营收复合增速更高（-2.9% vs -52.8%）
Cardio Diagnostics Holdings, Inc.是一家专注于精准心血管医疗的企业，开发并商业化整合遗传与表观遗传技术的诊断检测产品，可早期识别冠心病、心力衰竭等心血管疾病，主要服务美国市场的医疗机构、临床实验室与患者。
奎德尔奥索公司是美国的诊断医疗产品制造商，旗下产品面向全球市场销售，深耕体外诊断领域，为医疗机构及相关用户提供专业的检测解决方案，助力全球医疗健康服务效率提升。
CDIO vs QDEL — 直观对比
营收规模更大
QDEL
是对方的196877.6倍
$3.6K
营收增速更快
QDEL
高出17.5%
-21.2%
自由现金流更多
CDIO
多$88.8M
$-94.7M
两年增速更快
QDEL
近两年复合增速
-52.8%
损益表 — Q4 2025 vs Q3 2026
| 指标 | | |
|---|---|---|
| 营收 | $3.6K | $699.9M |
| 净利润 | — | $-733.0M |
| 毛利率 | — | — |
| 营业利润率 | — | -100.7% |
| 净利率 | — | -104.7% |
| 营收同比 | -21.2% | -3.7% |
| 净利润同比 | 3.6% | -3583.4% |
| 每股收益（稀释后） | — | $-10.78 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CDIOQDEL
| Q4 25 | $3.6K | — | ||
| Q3 25 | $2.9K | $699.9M | ||
| Q2 25 | $7.5K | $613.9M | ||
| Q1 25 | $940 | $692.8M | ||
| Q4 24 | $4.5K | $707.8M | ||
| Q3 24 | $6.6K | $727.1M | ||
| Q2 24 | $7.9K | $637.0M | ||
| Q1 24 | $15.9K | $711.0M |
净利润CDIOQDEL
| Q4 25 | — | — | ||
| Q3 25 | $-1.7M | $-733.0M | ||
| Q2 25 | $-1.7M | $-255.4M | ||
| Q1 25 | $-1.6M | $-12.7M | ||
| Q4 24 | — | $-178.4M | ||
| Q3 24 | $-1.4M | $-19.9M | ||
| Q2 24 | $-1.3M | $-147.7M | ||
| Q1 24 | $-4.2M | $-1.7B |
营业利润率CDIOQDEL
| Q4 25 | — | — | ||
| Q3 25 | -59950.9% | -100.7% | ||
| Q2 25 | -22457.5% | -29.4% | ||
| Q1 25 | -173463.8% | 4.7% | ||
| Q4 24 | — | -14.2% | ||
| Q3 24 | -21412.9% | 2.1% | ||
| Q2 24 | -16295.6% | -18.4% | ||
| Q1 24 | -26105.3% | -247.3% |
净利率CDIOQDEL
| Q4 25 | — | — | ||
| Q3 25 | -60053.8% | -104.7% | ||
| Q2 25 | -22517.7% | -41.6% | ||
| Q1 25 | -173943.0% | -1.8% | ||
| Q4 24 | — | -25.2% | ||
| Q3 24 | -21467.6% | -2.7% | ||
| Q2 24 | -16365.9% | -23.2% | ||
| Q1 24 | -26140.0% | -239.9% |
每股收益（稀释后）CDIOQDEL
| Q4 25 | — | — | ||
| Q3 25 | $-0.98 | $-10.78 | ||
| Q2 25 | $-0.97 | $-3.77 | ||
| Q1 25 | $-0.97 | $-0.19 | ||
| Q4 24 | — | $-2.54 | ||
| Q3 24 | $-1.73 | $-0.30 | ||
| Q2 24 | $-1.71 | $-2.20 | ||
| Q1 24 | $-5.93 | $-25.50 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $98.1M |
| 总债务越低越好 | — | $2.5B |
| 股东权益账面价值 | $7.0M | $2.0B |
| 总资产 | $7.8M | $5.7B |
| 负债/权益比越低杠杆越低 | — | 1.23× |
8季度趋势，按日历期对齐
现金及短期投资CDIOQDEL
| Q4 25 | — | — | ||
| Q3 25 | — | $98.1M | ||
| Q2 25 | — | $151.7M | ||
| Q1 25 | — | $127.1M | ||
| Q4 24 | — | $98.3M | ||
| Q3 24 | — | $143.7M | ||
| Q2 24 | — | $107.0M | ||
| Q1 24 | — | $78.5M |
总债务CDIOQDEL
| Q4 25 | — | — | ||
| Q3 25 | — | $2.5B | ||
| Q2 25 | — | $2.1B | ||
| Q1 25 | — | $2.1B | ||
| Q4 24 | — | $2.1B | ||
| Q3 24 | — | $2.2B | ||
| Q2 24 | — | $2.2B | ||
| Q1 24 | — | $2.2B |
股东权益CDIOQDEL
| Q4 25 | $7.0M | — | ||
| Q3 25 | $8.2M | $2.0B | ||
| Q2 25 | $9.7M | $2.8B | ||
| Q1 25 | $11.4M | $3.0B | ||
| Q4 24 | $9.6M | $3.0B | ||
| Q3 24 | $3.7M | $3.2B | ||
| Q2 24 | $3.1M | $3.2B | ||
| Q1 24 | $3.0M | $3.3B |
总资产CDIOQDEL
| Q4 25 | $7.8M | — | ||
| Q3 25 | $8.8M | $5.7B | ||
| Q2 25 | $10.4M | $6.4B | ||
| Q1 25 | $12.3M | $6.5B | ||
| Q4 24 | $10.6M | $6.4B | ||
| Q3 24 | $4.5M | $6.8B | ||
| Q2 24 | $4.0M | $6.7B | ||
| Q1 24 | $4.3M | $6.7B |
负债/权益比CDIOQDEL
| Q4 25 | — | — | ||
| Q3 25 | — | 1.23× | ||
| Q2 25 | — | 0.74× | ||
| Q1 25 | — | 0.70× | ||
| Q4 24 | — | 0.72× | ||
| Q3 24 | — | 0.68× | ||
| Q2 24 | — | 0.70× | ||
| Q1 24 | — | 0.68× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-5.7M | $-45.5M |
| 自由现金流经营现金流 - 资本支出 | $-5.9M | $-94.7M |
| 自由现金流率自由现金流/营收 | -166361.5% | -13.5% |
| 资本支出强度资本支出/营收 | 5269.1% | 7.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-10.5M | $-153.1M |
8季度趋势，按日历期对齐
经营现金流CDIOQDEL
| Q4 25 | $-5.7M | — | ||
| Q3 25 | $-1.4M | $-45.5M | ||
| Q2 25 | $-1.6M | $-46.8M | ||
| Q1 25 | $-1.4M | $65.6M | ||
| Q4 24 | $-5.0M | $63.7M | ||
| Q3 24 | $-1.2M | $117.9M | ||
| Q2 24 | $-1.2M | $-97.9M | ||
| Q1 24 | $-1.2M | $-700.0K |
自由现金流CDIOQDEL
| Q4 25 | $-5.9M | — | ||
| Q3 25 | $-1.6M | $-94.7M | ||
| Q2 25 | $-1.6M | $-84.3M | ||
| Q1 25 | $-1.4M | $9.4M | ||
| Q4 24 | $-5.2M | $16.5M | ||
| Q3 24 | $-1.2M | $71.4M | ||
| Q2 24 | $-1.4M | $-133.2M | ||
| Q1 24 | $-1.3M | $-66.8M |
自由现金流率CDIOQDEL
| Q4 25 | -166361.5% | — | ||
| Q3 25 | -54509.7% | -13.5% | ||
| Q2 25 | -21273.1% | -13.7% | ||
| Q1 25 | -149562.6% | 1.4% | ||
| Q4 24 | -115422.6% | 2.3% | ||
| Q3 24 | -17942.3% | 9.8% | ||
| Q2 24 | -17513.3% | -20.9% | ||
| Q1 24 | -7866.9% | -9.4% |
资本支出强度CDIOQDEL
| Q4 25 | 5269.1% | — | ||
| Q3 25 | 5703.5% | 7.0% | ||
| Q2 25 | 250.1% | 6.1% | ||
| Q1 25 | 615.6% | 8.1% | ||
| Q4 24 | 4759.9% | 6.7% | ||
| Q3 24 | 353.3% | 6.4% | ||
| Q2 24 | 2133.4% | 5.5% | ||
| Q1 24 | 125.5% | 9.3% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CDIO
暂无分部数据
QDEL
| Labs | $373.8M | 53% |
| Point Of Care | $164.6M | 24% |
| Immunohematology | $142.0M | 20% |
| Donor Screening | $14.7M | 2% |
| Molecular Diagnostics | $4.8M | 1% |
| Collaborative Arrangement Transaction With Party To Collaborative Arrangement | $2.1M | 0% |
